Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients. This study aimed to investigate the lifetime cost-effective value of IDegLira compared with its single component (Degludec or Liraglutide) and to ex...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |